Monte Rosa Therapeutics Inc’s recent filing unveils that its Director Leo Chandra P. acquired Company’s shares for reported $58383.0 on Mar 24 ’25. In the deal valued at $5.84 per share,10,000 shares were bought. As a result of this transaction, Leo Chandra P. now holds 10,000 shares worth roughly $44300.0.
Then, Versant Venture Capital VI, L. sold 89,990 shares, generating $869,240 in total proceeds. Upon selling the shares at $9.66, the 10% Owner now owns 2,007,948 shares.
Before that, Versant Venture Capital VI, L. sold 67,905 shares. Monte Rosa Therapeutics Inc shares valued at $621,801 were divested by the 10% Owner at a price of $9.16 per share. As a result of the transaction, Versant Venture Capital VI, L. now holds 1,573,453 shares, worth roughly $6.97 million.
Wells Fargo downgraded its Monte Rosa Therapeutics Inc [GLUE] rating to an Equal weight from a an Overweight in a research note published on December 19, 2024; the price target was decreased to $11 from $14. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in mid February with a ‘”an Outperform”‘ rating. Wells Fargo also remained covering GLUE and has increased its forecast on January 03, 2023 with a “an Overweight” recommendation from previously “an Equal weight” rating. UBS started covering the stock on October 13, 2022. It rated GLUE as “a Buy”.
Price Performance Review of GLUE
On Tuesday, Monte Rosa Therapeutics Inc [NASDAQ:GLUE] saw its stock jump 0.45% to $4.43. Over the last five days, the stock has gained 13.01%. Monte Rosa Therapeutics Inc shares have fallen nearly -36.17% since the year began. Nevertheless, the stocks have fallen -38.56% over the past one year. While a 52-week high of $12.40 was reached on 01/03/25, a 52-week low of $3.21 was recorded on 04/07/25. SMA at 50 days reached $5.72, while 200 days put it at $6.10.
Levels Of Support And Resistance For GLUE Stock
The 24-hour chart illustrates a support level at 4.34, which if violated will result in even more drops to 4.26. On the upside, there is a resistance level at 4.53. A further resistance level may holdings at 4.64. The Relative Strength Index (RSI) on the 14-day chart is 39.23, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.00, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 54.63%. Stochastics %K at 37.30% indicates the stock is a holding.
How much short interest is there in Monte Rosa Therapeutics Inc?
A steep rise in short interest was recorded in Monte Rosa Therapeutics Inc stocks on 2025-03-31, dropping by -2.63 million shares to a total of 5.41 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 8.04 million shares. There was a decline of -48.54%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 15, 2022 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
